21 questions to ask before you order from any regenerative biologics supplier, and the answers that should end the conversation.
21 questions
Printable
About 10 minutes
What's inside
21 questions in six sections, from FDA registration to recalls
The 361 HCT/P criteria in plain English
The red flags that should end the conversation
A printable version to keep supplier answers on file
You're in. Every resource in the library is unlocked on this device. See them all
This is an educational checklist, not legal or regulatory advice. Rules change and vary by state. Review your sourcing decisions with your own counsel and compliance advisor.
When you put a supplier's product in front of a patient, you are the one who has to stand behind where it came from. Send every supplier these questions in writing and keep their answers on file. A good supplier answers quickly and sends documents.
ARegistration and accreditation
BDonor eligibility and testing
CProcessing and quality
DRegulatory positioning
This section matters most. A product regulated only under section 361 of the Public Health Service Act has to meet every criterion in 21 CFR 1271.10(a):
It is minimally manipulated.
It is intended for homologous use only, meaning it does the same basic job in the recipient that the tissue did in the donor.
It is not combined with another article, with narrow exceptions such as water, crystalloids or a sterilizing, preserving or storage agent.
It either has no systemic effect and does not depend on the metabolic activity of living cells for its primary function, or it is for autologous use, use in a first- or second-degree blood relative, or reproductive use.
EStorage, shipping and traceability
FCommercial terms
Walk away if you hear
"FDA approved" about a product regulated under section 361
Disease or cure claims in their brochures, ads or sales calls
No FEI number, or one you can't find in the FDA database
"We don't share that" about donor testing or lot documents